Amrion
This article was originally published in The Tan Sheet
Executive Summary
FDA is investigating alleged violations of agency regulations "and other activities" committed by the company in 1989, when Amrion was "newly formed and under different management," firm says. Amrion said it submitted an offer of settlement to the Department of Justice but that it was rejected by DoJ on the basis that there is "some level of corporate liability." DoJ has issued a grand jury subpoena to the firm "for records to investigate the matter further," Amrion said, adding that it is cooperating with DoJ and FDA...